Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Metadata indicated Merck & Co., Inc., but the filing text is for Schering-Plough).
Reporting Period: Fiscal year ended December 31, 2002.
Business Overview: A global pharmaceutical holding company engaged in the discovery, development, manufacturing, and marketing of prescription drugs, animal health products, and consumer health products (OTC, foot care, sun care). Key therapeutic areas include allergy/respiratory, anti-infective/anticancer, cardiovascular, and dermatologicals.
Key Financial Metrics
Revenue: Consolidated net sales were $10,180 million in 2002, a 4% increase from $9,762 million in 2001.
Profit, Cash Flow, Margins, Debt, Liquidity: The filing text provided does not contain specific values for net income, operating margins, cash flow from operations, total debt, or liquidity ratios. These figures are incorporated by reference from the 2002 Annual Report to Shareholders.
Research and Development: Expenditures were $1,425 million in 2002 (14% of net sales), compared to $1,312 million in 2001.
Capital Expenditures: Included approximately $9 million for environmental control purposes.
Material Changes vs. Prior Period
- Allergy & Respiratory Sales: Declined 22% to $3,304 million. This was driven by a 43% drop in CLARITIN prescription sales ($1.8 billion vs. $3.2 billion in 2001) following the switch to OTC status in December 2002. This decline was partially offset by $598 million in sales for the new product CLARINEX.
- Anti-Infective & Anticancer Sales: Increased 64% to $3,733 million. The INTRON franchise (hepatitis C treatment) grew 89% to $2.736 billion.
- Cardiovascular Sales: Declined 30% to $433 million, primarily due to a 92% drop in K-DUR sales ($16 million vs. $216 million).
- OTC Sales: Increased 46% to $275 million, driven by the introduction of OTC CLARITIN ($105 million).
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary: Management anticipates a "rapid, sharp and material adverse effect" on results of operations for an indeterminate period due to the OTC switch of CLARITIN and the entry of generic competitors. The company expects competition to adversely affect the market share of PEG-INTRON and REBETOL following the approval of a competing pegylated interferon product in Q4 2002.
Legal and Regulatory Risks:
- FDA Consent Decree: The company agreed to a $500 million penalty (accrued in 2001) to resolve GMP compliance issues at New Jersey and Puerto Rico facilities. Failure to meet revalidation deadlines could result in additional payments capped at $175 million through 2005 and potential production halts.
- Government Investigations: Multiple investigations are ongoing regarding marketing practices, Medicaid rebates, and Average Wholesale Price (AWP) reporting. In February 2003, the company increased litigation reserves by $150 million related to these matters.
- Patent Litigation: A federal court ruled in August 2002 that certain claims of the desloratadine compound patent (protecting CLARITIN) were invalid. The company has appealed, with a decision expected in late 2003 or early 2004. Loss of this patent protection could allow generic competition.
- Securities Litigation: Class action lawsuits are pending regarding alleged violations of securities laws related to the disclosure of FDA manufacturing deficiencies.
Investor Verification Checklist
- Verify the full financial statements (Income Statement, Balance Sheet, Cash Flow) in the 2002 Annual Report to Shareholders, as specific profit and liquidity figures are not in this text.
- Monitor the status of the appeal regarding the desloratadine patent validity, as this directly impacts CLARITIN revenue protection.
- Track the progress of the FDA consent decree revalidation schedule to assess the risk of additional fines or production stoppages.
- Review updates on government investigations regarding Medicaid rebates and AWP reporting, noting the $150 million reserve increase.
- Assess the competitive landscape for the INTRON franchise following the Q4 2002 approval of competing hepatitis C therapies.